Xenon Pharmaceuticals Inc. vs Soleno Therapeutics, Inc.: SG&A Expense Trends

Biotech Giants: SG&A Expense Trends Unveiled

__timestampSoleno Therapeutics, Inc.Xenon Pharmaceuticals Inc.
Wednesday, January 1, 201429175135496000
Thursday, January 1, 201578782919786000
Friday, January 1, 201683667946792000
Sunday, January 1, 201766103817313000
Monday, January 1, 201865560008382000
Tuesday, January 1, 2019693000010803000
Wednesday, January 1, 2020875800012944000
Friday, January 1, 20211080600021967000
Saturday, January 1, 2022984400032810000
Sunday, January 1, 20231348100046542000
Loading chart...

Unleashing the power of data

SG&A Expense Trends: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing expenses is crucial for success. This analysis of SG&A (Selling, General, and Administrative) expenses from 2014 to 2023 reveals intriguing trends for Xenon Pharmaceuticals Inc. and Soleno Therapeutics, Inc. Over this period, Xenon Pharmaceuticals has consistently outpaced Soleno Therapeutics, with a remarkable 750% increase in SG&A expenses, peaking at $46.5 million in 2023. In contrast, Soleno Therapeutics saw a more modest 360% rise, reaching $13.5 million in the same year. This disparity highlights Xenon's aggressive growth strategy, possibly reflecting its investment in expanding operations and market reach. Meanwhile, Soleno's steadier increase suggests a more conservative approach. These trends offer valuable insights into the strategic priorities of these companies, providing investors and industry analysts with a clearer picture of their financial trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025